Stewart Cooper, M.D., Director, Kalmanovitz Liver Immunology Laboratory; Senior Scientist

California Pacific CURRENTS: The online journal of CPMC Research Institute

Improving the prevention and treatment of hepatitis B, hepatitis C, and other liver diseases

Research Overview

  • Dr. Cooper studies molecular and genetic changes underlying liver diseases including hepatitis B and C, and he uses genomic and proteomic approaches to uncover new therapeutic targets for the hepatitis virus.
  • Current research in the Cooper lab includes investigations of how natural killer cells, T cells, and hybrid natural killer T cells may interact to clear hepatitis C, and how related sets of genes influence immune response.
  • Dr. Cooper directs the Kalmanovitz Liver Immunology Laboratory at CPMC, and leads translational research to identify immunological influences on disease outcomes in patients with hepatitis C (including those undergoing liver transplantation).
  • Under Dr. Cooper’s leadership, validated biomarkers for liver and biliary diseases will be used to personalize treatment and help predict an individual’s response to therapy.

Training


Dr. Cooper received his M.D. at Welsh National School of Medicine in Cardiff, Wales (UK). He completed residency training at the University Hospital of Wales and a fellowship in gastroenterology at Stanford University School of Medicine in Palo Alto, California.


 

Publication Search

Publications

Lok AS, Ganova-Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, Ghany MG, Hepatitis B Research Network (HBRN)., Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat

Cooper S, Umeweni N, Knight H, McVeigh G, Sofosbuvir-velpatasvir for treating chronic hepatitis C. Lancet Gastroenterol Hepatol

Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, Hoofnagle JH, Hepatitis B Research Network (HBRN)., Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat

Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM, Hepatitis B Research Network., Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology

Publicover J, Jespersen JM, Johnson AJ, Nishimura SL, Goodsell A, Wakil AE, Rosenthal P, Pai E, Avanesyan L, Cooper S, Baron JL, Liver capsule: Age-influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man. Hepatology

Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, Lau D, Lisker-Melman M, Sanyal A, Lok AS, HBRN., Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology

VIEW ALL
Publication Feed

Publications

Lok AS, Ganova-Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, Ghany MG, Hepatitis B Research Network (HBRN). Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment. J Viral Hepat.

Stewart Cooper, M.D., Director, Kalmanovitz Liver Immunology Laboratory; Senior Scientist
Primary Research Interests
  • Investigations of how natural killer cells, T cells, and hybrid natural killer T cells interact to clear hepatitis C
  • Development and validation of biomarkers for liver and biliary diseases
  • Studies on autoimmune liver disease, complications of liver disease, hemochromatosis, hepatic encephalopathy, and liver cancer

Hepatology Clinical Trials

Lab Members

Adil (Ed) Wakil, M.D.
Associate Chief, Division of Hepatology at California Pacific Medical Center; Associate Director of the Kalmanovitz Liver Immunology Laboratory
Dr. Lia Avanesyan, Ph.D.
Post-doctoral Fellow
Adrian Wadley, B.Sc.
El Hefni Liver Biorepository Manager